CIK 0001618835
- Non-accelerated filer
- Smaller reporting company
Evofem Biosciences, Inc.
Sign in to watch- Ticker
- EVFM
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208527075
- Phone
- +1 858-550-1900
- Business address
- 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130
- Former names
- Neothetics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Executive Officer bought 45,249 shares at $2.28 ($103,168)
- 4 Grant or award Chief Executive Officer acquired 500,000 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 200,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 200,000 shares (grant or award)
- 4 Grant or award General Counsel and Secretary acquired 200,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 200,000 shares (grant or award)
- 4 Open-market buy Chief Financial Officer bought 7,760 shares at $2.17 ($16,839)
- 4 Open-market buy General Counsel and Secretary bought 9,090 shares at $2.20 ($19,998)
- 4 Open-market buy Chief Commercial Officer bought 4,000 shares at an average $2.24 ($8,950)
- 4 Open-market sale Chief Executive Officer sold 122,500 shares at $3.26 ($399,350)
- 4 Open-market sale 10% owner sold 9,138,504 shares at $0.23 ($2,101,856)
- 4 Shares withheld for taxes Chief Commercial Officer gave up 20,381 shares (to pay taxes)
- 4 Open-market buy Director bought 5,250 shares at $2.99 ($15,698)
- 4/A Open-market buy Director bought 5,000 shares at $2.85 ($14,250)
- 4 Open-market buy Director bought 5,000 shares at $2.85 ($14,250)
- 4 Open-market buy Director bought 5,000 shares at $2.94 ($14,700)
- 4 Open-market buy Chief Financial Officer bought 8,500 shares at $3.14 ($26,690)
- 4 Open-market sale 10% owner sold 9,138,504 shares at $3.21 ($29,325,459)
- 3 Insider Initial Statement of Ownership
Page 3 of 15 · 281 filings